Abstract

Frataxin deficiency, responsible for Friedreich’s ataxia (FRDA), is crucial for cell survival since it critically affects viability of neurons, pancreatic beta cells and cardiomyocytes. In FRDA, the heart is frequently affected with typical manifestation of hypertrophic cardiomyopathy, which can progress to heart failure and cause premature death. A microarray analysis performed on FRDA patient’s lymphoblastoid cells stably reconstituted with frataxin, indicated HS-1-associated protein X-1 (HAX-1) as the most significantly upregulated transcript (FC = +2, P < 0.0006). quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) and western blot analysis performed on (I) HEK293 stably transfected with empty vector compared to wild-type frataxin and (II) lymphoblasts from FRDA patients show that low frataxin mRNA and protein expression correspond to reduced levels of HAX-1. Frataxin overexpression and silencing were also performed in the AC16 human cardiomyocyte cell line. HAX-1 protein levels are indeed regulated through frataxin modulation. Moreover, correlation between frataxin and HAX-1 was further evaluated in peripheral blood mononuclear cells (PBMCs) from FRDA patients and from non-related healthy controls. A regression model for frataxin which included HAX-1, group membership and group* HAX-1 interaction revealed that frataxin and HAX-1 are associated both at mRNA and protein levels. Additionally, a linked expression of FXN, HAX-1 and antioxidant defence proteins MnSOD and Nrf2 was observed both in PBMCs and AC16 cardiomyocytes. Our results suggest that HAX-1 could be considered as a potential biomarker of cardiac disease in FRDA and the evaluation of its expression might provide insights into its pathogenesis as well as improving risk stratification strategies.

Introduction

Friedreich’s ataxia (FRDA, OMIM#229300) is a rare hereditary disease due to a deficiency of the mitochondrial protein frataxin (FXN) caused in most cases by homozygous hyperexpansion of Guanine Adenine Adenine (GAA) triplets that severely reduces FXN gene transcription (1). FXN deficiency critically affects viability of neurons, pancreatic beta cells and cardiomyocytes in humans (2). Besides the characteristic features of spinocerebellar ataxia, two-thirds of patients develop hypertrophic cardiomyopathy, which often progress to heart failure, finally causing premature death (3). Searching for genes involved in the disease pathogenesis that could be modulated by FXN levels, a microarray analysis was performed in FXN-deficient lymphoblastoid cells derived from a FRDA patient stably reconstituted with wild-type FXN. HS-1-associated protein X-1 (HAX-1) resulted the highest upregulated transcript in the FXN-reconstituted cells compared to empty-vector transfected cells.

HAX-1 comprises a ubiquitously expressed family of proteins with diverse-binding partners that plays key roles in the regulation of cell survival (4). HAX-1 proteins, ranging in size from 26 to 35 kDa, result from complex alternative splicing events. Deregulation of the expression levels and subcellular distribution of HAX-1 is associated with the development and progression of severe diseases, including cancer, psoriasis, congenital neutropenia and neurological disorders (4–6). HAX-1 has been identified as an antiapoptotic protein required for the survival of different cell types such as cerebellar neurons (7) and cardiomyocytes (8). HAX-1 is indeed involved in the coordination of the network assembly of actin structures with KV3.3 channels, the dysfunction of which is correlated with spinocerebellar ataxia 13 (9). Two different HAX-1 isoforms, one proapoptotic (human v4) and the other antiapoptotic (human v1), have been reported to modulate cardiac cell survival and death through homo- or heterodimerization (10). AQ10: These data suggest the involvement of HAX-1 isoforms in apoptosis modulation and cell survival. HAX-1 is highly expressed in the heart (11) where it plays a role in cardioprotection. HAX-1 was shown to undertake an antiapoptotic function in cardiomyocytes by interacting directly with caspase-9 and therefore inhibiting its activity (12). Moreover, HAX-1 was identified as a regulator of contractility and calcium cycling (13). HAX-1 can associate with sarcoplasmic reticulum Ca-ATPase (SERCA2a) (14) and its regulating protein phospholamban (15), which both play a central role in modulating calcium homeostasis, important for cardiac function (16). Interestingly, HAX-1 heterozygous-deficient hearts exhibit increases in infarct size in response to ischemia/reperfusion injury. Conversely, overexpression of HAX-1 improves contractile recovery coupled with reduced myocardial infarction (8). HAX-1 protective effects can be mediated through the modulation of cyclophilin-D levels that further regulate the mitochondrial permeability transition pore opening (17).

Therefore, we sought to examine the antiapoptotic HAX-1.v1 (named HAX-1 throughout the text) expression in FRDA patients. We found a positive correlation between FXN and HAX-1 expression. In addition, a linked expression of FXN, HAX-1 and antioxidant defence proteins MnSOD and Nrf2 was observed both in peripheral blood mononuclear cells (PBMCs) from FRDA patients and from non-related healthy controls and in AC16 human cardiomyocytes. Moreover, a significant modulation of HAX-1 expression by FXN levels in AC16 human cardiomyocytes therefore suggests HAX-1 involvement in the development of cardiac disease in FRDA.

Results

HAX-1 expression is regulated by FXN levels

In this study, we analyzed, by a comparative microarray approach, the transcriptome profile induced by FXN overexpression in FXN-deficient lymphoblastoid cells (GM15850, derived from a FRDA patient) stably reconstituted with wild-type FXN (FXN-cells) compared to GM15850 cells transfected with empty vector (EMPTY-cells). After data normalization, 667 genes were identified as differentially expressed with significant P-value (P < 0.05) (Supplementary Material, Table S1). Among these significantly expressed genes, 91 resulted differentially expressed as either < 0.5 or > 1.5 fold changes (FC, Table 1). Of these differentially expressed genes, only 7 resulted downregulated. Among them, C19orf12 (ID BC004957_1; FC = −2.2; P < 0.05) encodes a small transmembrane protein with unknown function; however, mutations in C19orf12 cause a form of neurodegeneration with brain iron accumulation (NBIA4) (18). Among the upregulated genes, the most significantly upregulated transcript, i.e. clone XM_095613_1 (FC = +2.1; P < 0.0005), was subsequently withdrawn from NCBI database. We thus focused our attention on BC005240_1 transcript (FC = +2; P < 0.0006), which corresponds to HS-1-associated protein X-1 (HAX-1) and analyzed its expression in FRDA.

Table 1

The top 91 differentially expressed genes in GM15850 cells stably reconstituted with frataxin, sorted according to increasing P-values

IDNameFCP-value
1XM_095613_1Similar to polycystic kidney disease 1 homolog; polycystin-1; loc1692862.10.0005
2BC005240_1Homo sapiens HCLS1-associated protein X-120.0006
3AL138828_3ba472e5.2.2 (novel protein; isoform 2); ba472e5.220.0007
4NM_004852_1One cut domain; family member 2; onecut21.90.0007
5XM_171898_1Similar to transmembrane activator and CAML interactor; loc2552621.90.0008
6AB051077_1Peroxin pex6p; pex61.60.0009
7AJ010482_1Myopodin protein; myopodin2.10.001
8XM_092643_1Similar to b29 protein; loc1655241.90.001
9AK075317_1cDNA clone moderately similar to Mus musculus gng3lg mRNA; unnamed protein product2.10.001
10AB062787_1Triggering receptor trem-2v2.30.0011
11AY014403_1Kinesin-like protein rbkin1; rbkin1.50.0013
12AF241254_1Angiotensin converting enzyme-like protein1.80.0016
13XM_070666_1Similar to junctophilin 1; mitsugumin72; junctophilin type1; jph12.10.0017
14XM_171974_1Similar to zinc finger protein 91 (hpf7; htf10); loc2566961.70.0018
15BC028101_1Bruno-like 5; RNA-binding protein (drosophila)1.50.0019
16XM_063253_1Similar to NADH dehydrogenase (ubiquinone) 1 alpha subcomplex; 4; loc1226672.10.0021
17XM_058961_1Similar to riken cDNA 4021401a16; loc1260031.60.0026
18XM_167626_1Hypothetical protein xp_167626; loc2209321.60.0027
19NM_139120_1yy1-associated protein; isoform 4; yap1.50.0031
20AK022552_1cDNA clone highly similar to Rattus norvegicus rexo70 mRNA; unnamed protein product.1.50.0031
21XM_106383_1Hypothetical protein xp_106383; loc1669441.80.0031
22AK097855_1cDNA clone unnamed protein product1.60.0032
23AK074215_1cDNA clone unnamed protein product1.50.00324
24AK074686_1cDNA clone unnamed protein product1.60.0036
25XM_067012_1Similar to ptpn13-like; y-linked; testis-specific PTP-BL-related protein on y; loc1400161.60.0041
26XM_170930_1Similar to dj830a10.1 (ecotropic viral integration site 5); loc2559781.60.0045
27XM_171784_1Similar to cg15057 gene product; loc25631320.0047
28XM_167035_1Similar to heparan sulfate d-glucosaminyl 3-o-sulfotransferase 1 precursor; heparin-glucosamine 3-o-sulfotransferase; loc2225371.60.0047
29XM_115902_1Similar to poly(a) binding protein; cytoplasmic 1; loc2070611.50.0053
30AK091802_1cDNA clone unnamed protein product.1.60.0053
31XM_097203_1Hypothetical protein xp_097203; loc1471571.50.0053
32BC028048_1Unknown (protein for mgc:40108)1.60.0058
33XM_166973_1Similar to b24o18.3 (pom121 membrane glycoprotein (rat homolog)-like 2); loc2195491.50.0058
34AK056874_1cDNA clone unnamed protein product.1.70.0062
35XM_064853_1Similar to zinc finger protein 347; zinc finger 1111; loc1258911.60.0066
36XM_119769_1Hypothetical protein xp_119769; loc2054051.60.0066
37AL138875_3ba103j18.1.2 (novel protein; isoform 2); ba103j18.11.80.0067
38BC012183_1Unknown (protein for mgc:20470)1.70.0074
39XM_065532_1Similar to hypothetical protein flj13725; kiaa1930 protein; loc1300171.50.0075
40XM_032161_1Hypothetical protein xp_032161; loc904941.70.0079
41XM_033004_1Hypothetical protein bc005107; loc906251.80.0083
42XM_090444_1Similar to synaptotagmin 10; loc1606991.60.0085
43AK091473_1cDNA clone unnamed protein product20.0086
44XM_166111_1Similar to snap-25-interacting protein; loc2196720.50.01
45AL035464_1dj1043e3.1 (novel protein); dj1043e3.11.60.0111
46AK026702_1Homo sapiens cDNA: flj23049 fis; clone lng02559; unnamed protein product20.0112
47AB014569_1kiaa0669 protein; kiaa06690.40.0126
48BC030602_1Similar to myosin IC1.80.0126
49AB062487_1ok/sw-cl.68; ok/sw-cl.681.60.0134
50AF123074_1Cytoplasmic dynein intermediate chain 11.80.0139
51BC034327_1Similar to kiaa1683 protein1.80.0160
52NM_002258_1Killer cell lectin-like receptor subfamily b; member 1; klrb11.50.0167
53AF254067_1Interleukin 21 receptor; IL21R1.60.0198
54AF230904_1c-Cbl-interacting protein; cin850.50.0201
55XM_096879_1Hypothetical protein xp_096879; loc1458281.60.0212
56NM_001813_1Centromere protein e; CENPE2.50.0212
57XM_173595_1Hypothetical protein xp_173595; loc2542340.40.0213
58BC009870_1Gamma tubulin ring complex protein (76p gene)1.50.0226
59XM_045632_1Similar to hypothetical protein flj11292; loc925391.50.0227
60XM_116109_1Similar to cg1364 gene product; loc2016152.20.0229
61AK091107_1cDNA clone unnamed protein product.0.40.0252
62XM_171089_1Similar to nephronectin; loc2557431.60.0255
63XM_170392_1Similar to beta-1;3-galactosyl-o-glycosyl-glycoprotein beta-1;6-n-acetylglucosaminyltransferase (core 2 branching enzyme) (core2-glcnac-transferase) (c2gnt) (core 2 gnt); loc2231011.70.0277
64XM_167601_1Similar to knockout; loc2197351.50.0306
65AF269161_1c21orf7 form a1.60.0311
66XM_058513_1Similar to riken cDNA 4921513o20; loc1208921.50.0320
67XM_071224_1Similar to putative gene with similarity to zinc finger proteins; loc1401601.60.0321
68BC020955_1Similar to hypothetical protein flj110461.70.0323
69BC031660_1Similar to loc1660751.80.0336
70NM_015847_1Methyl-cpg binding domain protein 1; isoform pcm1; mbd11.60.0339
71XM_066779_1Similar to sarcoma antigen; putative tumor antigen; loc1395871.60.0341
72BC004957_1Similar to riken cDNA 1600014c10 gene0.50.0345
73BC012184_1Unknown (protein for mgc:20471)1.70.0347
74AK095926_1cDNA clone unnamed protein product.1.50.0373
75XM_067647_1Similar to 60s ribosomal protein l23a; loc1320661.60.0383
76BC015338_1Unknown (protein for mgc:21282)1.70.0383
77XM_166207_1Similar to riken cDNA 2 410 018 m14; loc2195411.60.0388
78XM_094365_1Similar to early b-cell factor (olfactory neuronal transcription factor 1); loc1672521.50.0392
79D01038_1vla-3 alpha subunit1.50.0393
80BC007653_1Unknown (protein for image:3610013)1.60.0399
81NM_022442_1Ubiquitin-conjugating enzyme e2 variant 1; isoform c; ube2v11.60.0409
82AF268387_1Laryngeal carcinoma-related protein 11.60.0416
83XM_168471_1Hypothetical protein xp_168471; loc2221821.50.0426
84XM_088886_1Similar to c4b-binding protein alpha chain precursor (c4bp) (proline-rich protein) (prp); loc1634261.70.0430
85XM_116262_1Similar to platelet basic protein precursor (PBP) (small inducible cytokine b7) (cxcl7); loc2019600.40.0431
86XM_097883_1Hypothetical protein xp_097883; loc1502731.70.0440
87XM_118021_1Hypothetical protein xp_118021; loc2037661.50.0441
88AK001268_1cDNA clone unnamed protein product1.80.0447
89NM_139238_1adam-ts-related protein 1; isoform 1; adamtsl11.50.0471
90AF116720_1pro30151.60.0487
91AF319633_1Putative potassium channel kiaa00271.70.0490
IDNameFCP-value
1XM_095613_1Similar to polycystic kidney disease 1 homolog; polycystin-1; loc1692862.10.0005
2BC005240_1Homo sapiens HCLS1-associated protein X-120.0006
3AL138828_3ba472e5.2.2 (novel protein; isoform 2); ba472e5.220.0007
4NM_004852_1One cut domain; family member 2; onecut21.90.0007
5XM_171898_1Similar to transmembrane activator and CAML interactor; loc2552621.90.0008
6AB051077_1Peroxin pex6p; pex61.60.0009
7AJ010482_1Myopodin protein; myopodin2.10.001
8XM_092643_1Similar to b29 protein; loc1655241.90.001
9AK075317_1cDNA clone moderately similar to Mus musculus gng3lg mRNA; unnamed protein product2.10.001
10AB062787_1Triggering receptor trem-2v2.30.0011
11AY014403_1Kinesin-like protein rbkin1; rbkin1.50.0013
12AF241254_1Angiotensin converting enzyme-like protein1.80.0016
13XM_070666_1Similar to junctophilin 1; mitsugumin72; junctophilin type1; jph12.10.0017
14XM_171974_1Similar to zinc finger protein 91 (hpf7; htf10); loc2566961.70.0018
15BC028101_1Bruno-like 5; RNA-binding protein (drosophila)1.50.0019
16XM_063253_1Similar to NADH dehydrogenase (ubiquinone) 1 alpha subcomplex; 4; loc1226672.10.0021
17XM_058961_1Similar to riken cDNA 4021401a16; loc1260031.60.0026
18XM_167626_1Hypothetical protein xp_167626; loc2209321.60.0027
19NM_139120_1yy1-associated protein; isoform 4; yap1.50.0031
20AK022552_1cDNA clone highly similar to Rattus norvegicus rexo70 mRNA; unnamed protein product.1.50.0031
21XM_106383_1Hypothetical protein xp_106383; loc1669441.80.0031
22AK097855_1cDNA clone unnamed protein product1.60.0032
23AK074215_1cDNA clone unnamed protein product1.50.00324
24AK074686_1cDNA clone unnamed protein product1.60.0036
25XM_067012_1Similar to ptpn13-like; y-linked; testis-specific PTP-BL-related protein on y; loc1400161.60.0041
26XM_170930_1Similar to dj830a10.1 (ecotropic viral integration site 5); loc2559781.60.0045
27XM_171784_1Similar to cg15057 gene product; loc25631320.0047
28XM_167035_1Similar to heparan sulfate d-glucosaminyl 3-o-sulfotransferase 1 precursor; heparin-glucosamine 3-o-sulfotransferase; loc2225371.60.0047
29XM_115902_1Similar to poly(a) binding protein; cytoplasmic 1; loc2070611.50.0053
30AK091802_1cDNA clone unnamed protein product.1.60.0053
31XM_097203_1Hypothetical protein xp_097203; loc1471571.50.0053
32BC028048_1Unknown (protein for mgc:40108)1.60.0058
33XM_166973_1Similar to b24o18.3 (pom121 membrane glycoprotein (rat homolog)-like 2); loc2195491.50.0058
34AK056874_1cDNA clone unnamed protein product.1.70.0062
35XM_064853_1Similar to zinc finger protein 347; zinc finger 1111; loc1258911.60.0066
36XM_119769_1Hypothetical protein xp_119769; loc2054051.60.0066
37AL138875_3ba103j18.1.2 (novel protein; isoform 2); ba103j18.11.80.0067
38BC012183_1Unknown (protein for mgc:20470)1.70.0074
39XM_065532_1Similar to hypothetical protein flj13725; kiaa1930 protein; loc1300171.50.0075
40XM_032161_1Hypothetical protein xp_032161; loc904941.70.0079
41XM_033004_1Hypothetical protein bc005107; loc906251.80.0083
42XM_090444_1Similar to synaptotagmin 10; loc1606991.60.0085
43AK091473_1cDNA clone unnamed protein product20.0086
44XM_166111_1Similar to snap-25-interacting protein; loc2196720.50.01
45AL035464_1dj1043e3.1 (novel protein); dj1043e3.11.60.0111
46AK026702_1Homo sapiens cDNA: flj23049 fis; clone lng02559; unnamed protein product20.0112
47AB014569_1kiaa0669 protein; kiaa06690.40.0126
48BC030602_1Similar to myosin IC1.80.0126
49AB062487_1ok/sw-cl.68; ok/sw-cl.681.60.0134
50AF123074_1Cytoplasmic dynein intermediate chain 11.80.0139
51BC034327_1Similar to kiaa1683 protein1.80.0160
52NM_002258_1Killer cell lectin-like receptor subfamily b; member 1; klrb11.50.0167
53AF254067_1Interleukin 21 receptor; IL21R1.60.0198
54AF230904_1c-Cbl-interacting protein; cin850.50.0201
55XM_096879_1Hypothetical protein xp_096879; loc1458281.60.0212
56NM_001813_1Centromere protein e; CENPE2.50.0212
57XM_173595_1Hypothetical protein xp_173595; loc2542340.40.0213
58BC009870_1Gamma tubulin ring complex protein (76p gene)1.50.0226
59XM_045632_1Similar to hypothetical protein flj11292; loc925391.50.0227
60XM_116109_1Similar to cg1364 gene product; loc2016152.20.0229
61AK091107_1cDNA clone unnamed protein product.0.40.0252
62XM_171089_1Similar to nephronectin; loc2557431.60.0255
63XM_170392_1Similar to beta-1;3-galactosyl-o-glycosyl-glycoprotein beta-1;6-n-acetylglucosaminyltransferase (core 2 branching enzyme) (core2-glcnac-transferase) (c2gnt) (core 2 gnt); loc2231011.70.0277
64XM_167601_1Similar to knockout; loc2197351.50.0306
65AF269161_1c21orf7 form a1.60.0311
66XM_058513_1Similar to riken cDNA 4921513o20; loc1208921.50.0320
67XM_071224_1Similar to putative gene with similarity to zinc finger proteins; loc1401601.60.0321
68BC020955_1Similar to hypothetical protein flj110461.70.0323
69BC031660_1Similar to loc1660751.80.0336
70NM_015847_1Methyl-cpg binding domain protein 1; isoform pcm1; mbd11.60.0339
71XM_066779_1Similar to sarcoma antigen; putative tumor antigen; loc1395871.60.0341
72BC004957_1Similar to riken cDNA 1600014c10 gene0.50.0345
73BC012184_1Unknown (protein for mgc:20471)1.70.0347
74AK095926_1cDNA clone unnamed protein product.1.50.0373
75XM_067647_1Similar to 60s ribosomal protein l23a; loc1320661.60.0383
76BC015338_1Unknown (protein for mgc:21282)1.70.0383
77XM_166207_1Similar to riken cDNA 2 410 018 m14; loc2195411.60.0388
78XM_094365_1Similar to early b-cell factor (olfactory neuronal transcription factor 1); loc1672521.50.0392
79D01038_1vla-3 alpha subunit1.50.0393
80BC007653_1Unknown (protein for image:3610013)1.60.0399
81NM_022442_1Ubiquitin-conjugating enzyme e2 variant 1; isoform c; ube2v11.60.0409
82AF268387_1Laryngeal carcinoma-related protein 11.60.0416
83XM_168471_1Hypothetical protein xp_168471; loc2221821.50.0426
84XM_088886_1Similar to c4b-binding protein alpha chain precursor (c4bp) (proline-rich protein) (prp); loc1634261.70.0430
85XM_116262_1Similar to platelet basic protein precursor (PBP) (small inducible cytokine b7) (cxcl7); loc2019600.40.0431
86XM_097883_1Hypothetical protein xp_097883; loc1502731.70.0440
87XM_118021_1Hypothetical protein xp_118021; loc2037661.50.0441
88AK001268_1cDNA clone unnamed protein product1.80.0447
89NM_139238_1adam-ts-related protein 1; isoform 1; adamtsl11.50.0471
90AF116720_1pro30151.60.0487
91AF319633_1Putative potassium channel kiaa00271.70.0490

GenBank identity number (ID) and FC in gene expression are also displayed.

Table 1

The top 91 differentially expressed genes in GM15850 cells stably reconstituted with frataxin, sorted according to increasing P-values

IDNameFCP-value
1XM_095613_1Similar to polycystic kidney disease 1 homolog; polycystin-1; loc1692862.10.0005
2BC005240_1Homo sapiens HCLS1-associated protein X-120.0006
3AL138828_3ba472e5.2.2 (novel protein; isoform 2); ba472e5.220.0007
4NM_004852_1One cut domain; family member 2; onecut21.90.0007
5XM_171898_1Similar to transmembrane activator and CAML interactor; loc2552621.90.0008
6AB051077_1Peroxin pex6p; pex61.60.0009
7AJ010482_1Myopodin protein; myopodin2.10.001
8XM_092643_1Similar to b29 protein; loc1655241.90.001
9AK075317_1cDNA clone moderately similar to Mus musculus gng3lg mRNA; unnamed protein product2.10.001
10AB062787_1Triggering receptor trem-2v2.30.0011
11AY014403_1Kinesin-like protein rbkin1; rbkin1.50.0013
12AF241254_1Angiotensin converting enzyme-like protein1.80.0016
13XM_070666_1Similar to junctophilin 1; mitsugumin72; junctophilin type1; jph12.10.0017
14XM_171974_1Similar to zinc finger protein 91 (hpf7; htf10); loc2566961.70.0018
15BC028101_1Bruno-like 5; RNA-binding protein (drosophila)1.50.0019
16XM_063253_1Similar to NADH dehydrogenase (ubiquinone) 1 alpha subcomplex; 4; loc1226672.10.0021
17XM_058961_1Similar to riken cDNA 4021401a16; loc1260031.60.0026
18XM_167626_1Hypothetical protein xp_167626; loc2209321.60.0027
19NM_139120_1yy1-associated protein; isoform 4; yap1.50.0031
20AK022552_1cDNA clone highly similar to Rattus norvegicus rexo70 mRNA; unnamed protein product.1.50.0031
21XM_106383_1Hypothetical protein xp_106383; loc1669441.80.0031
22AK097855_1cDNA clone unnamed protein product1.60.0032
23AK074215_1cDNA clone unnamed protein product1.50.00324
24AK074686_1cDNA clone unnamed protein product1.60.0036
25XM_067012_1Similar to ptpn13-like; y-linked; testis-specific PTP-BL-related protein on y; loc1400161.60.0041
26XM_170930_1Similar to dj830a10.1 (ecotropic viral integration site 5); loc2559781.60.0045
27XM_171784_1Similar to cg15057 gene product; loc25631320.0047
28XM_167035_1Similar to heparan sulfate d-glucosaminyl 3-o-sulfotransferase 1 precursor; heparin-glucosamine 3-o-sulfotransferase; loc2225371.60.0047
29XM_115902_1Similar to poly(a) binding protein; cytoplasmic 1; loc2070611.50.0053
30AK091802_1cDNA clone unnamed protein product.1.60.0053
31XM_097203_1Hypothetical protein xp_097203; loc1471571.50.0053
32BC028048_1Unknown (protein for mgc:40108)1.60.0058
33XM_166973_1Similar to b24o18.3 (pom121 membrane glycoprotein (rat homolog)-like 2); loc2195491.50.0058
34AK056874_1cDNA clone unnamed protein product.1.70.0062
35XM_064853_1Similar to zinc finger protein 347; zinc finger 1111; loc1258911.60.0066
36XM_119769_1Hypothetical protein xp_119769; loc2054051.60.0066
37AL138875_3ba103j18.1.2 (novel protein; isoform 2); ba103j18.11.80.0067
38BC012183_1Unknown (protein for mgc:20470)1.70.0074
39XM_065532_1Similar to hypothetical protein flj13725; kiaa1930 protein; loc1300171.50.0075
40XM_032161_1Hypothetical protein xp_032161; loc904941.70.0079
41XM_033004_1Hypothetical protein bc005107; loc906251.80.0083
42XM_090444_1Similar to synaptotagmin 10; loc1606991.60.0085
43AK091473_1cDNA clone unnamed protein product20.0086
44XM_166111_1Similar to snap-25-interacting protein; loc2196720.50.01
45AL035464_1dj1043e3.1 (novel protein); dj1043e3.11.60.0111
46AK026702_1Homo sapiens cDNA: flj23049 fis; clone lng02559; unnamed protein product20.0112
47AB014569_1kiaa0669 protein; kiaa06690.40.0126
48BC030602_1Similar to myosin IC1.80.0126
49AB062487_1ok/sw-cl.68; ok/sw-cl.681.60.0134
50AF123074_1Cytoplasmic dynein intermediate chain 11.80.0139
51BC034327_1Similar to kiaa1683 protein1.80.0160
52NM_002258_1Killer cell lectin-like receptor subfamily b; member 1; klrb11.50.0167
53AF254067_1Interleukin 21 receptor; IL21R1.60.0198
54AF230904_1c-Cbl-interacting protein; cin850.50.0201
55XM_096879_1Hypothetical protein xp_096879; loc1458281.60.0212
56NM_001813_1Centromere protein e; CENPE2.50.0212
57XM_173595_1Hypothetical protein xp_173595; loc2542340.40.0213
58BC009870_1Gamma tubulin ring complex protein (76p gene)1.50.0226
59XM_045632_1Similar to hypothetical protein flj11292; loc925391.50.0227
60XM_116109_1Similar to cg1364 gene product; loc2016152.20.0229
61AK091107_1cDNA clone unnamed protein product.0.40.0252
62XM_171089_1Similar to nephronectin; loc2557431.60.0255
63XM_170392_1Similar to beta-1;3-galactosyl-o-glycosyl-glycoprotein beta-1;6-n-acetylglucosaminyltransferase (core 2 branching enzyme) (core2-glcnac-transferase) (c2gnt) (core 2 gnt); loc2231011.70.0277
64XM_167601_1Similar to knockout; loc2197351.50.0306
65AF269161_1c21orf7 form a1.60.0311
66XM_058513_1Similar to riken cDNA 4921513o20; loc1208921.50.0320
67XM_071224_1Similar to putative gene with similarity to zinc finger proteins; loc1401601.60.0321
68BC020955_1Similar to hypothetical protein flj110461.70.0323
69BC031660_1Similar to loc1660751.80.0336
70NM_015847_1Methyl-cpg binding domain protein 1; isoform pcm1; mbd11.60.0339
71XM_066779_1Similar to sarcoma antigen; putative tumor antigen; loc1395871.60.0341
72BC004957_1Similar to riken cDNA 1600014c10 gene0.50.0345
73BC012184_1Unknown (protein for mgc:20471)1.70.0347
74AK095926_1cDNA clone unnamed protein product.1.50.0373
75XM_067647_1Similar to 60s ribosomal protein l23a; loc1320661.60.0383
76BC015338_1Unknown (protein for mgc:21282)1.70.0383
77XM_166207_1Similar to riken cDNA 2 410 018 m14; loc2195411.60.0388
78XM_094365_1Similar to early b-cell factor (olfactory neuronal transcription factor 1); loc1672521.50.0392
79D01038_1vla-3 alpha subunit1.50.0393
80BC007653_1Unknown (protein for image:3610013)1.60.0399
81NM_022442_1Ubiquitin-conjugating enzyme e2 variant 1; isoform c; ube2v11.60.0409
82AF268387_1Laryngeal carcinoma-related protein 11.60.0416
83XM_168471_1Hypothetical protein xp_168471; loc2221821.50.0426
84XM_088886_1Similar to c4b-binding protein alpha chain precursor (c4bp) (proline-rich protein) (prp); loc1634261.70.0430
85XM_116262_1Similar to platelet basic protein precursor (PBP) (small inducible cytokine b7) (cxcl7); loc2019600.40.0431
86XM_097883_1Hypothetical protein xp_097883; loc1502731.70.0440
87XM_118021_1Hypothetical protein xp_118021; loc2037661.50.0441
88AK001268_1cDNA clone unnamed protein product1.80.0447
89NM_139238_1adam-ts-related protein 1; isoform 1; adamtsl11.50.0471
90AF116720_1pro30151.60.0487
91AF319633_1Putative potassium channel kiaa00271.70.0490
IDNameFCP-value
1XM_095613_1Similar to polycystic kidney disease 1 homolog; polycystin-1; loc1692862.10.0005
2BC005240_1Homo sapiens HCLS1-associated protein X-120.0006
3AL138828_3ba472e5.2.2 (novel protein; isoform 2); ba472e5.220.0007
4NM_004852_1One cut domain; family member 2; onecut21.90.0007
5XM_171898_1Similar to transmembrane activator and CAML interactor; loc2552621.90.0008
6AB051077_1Peroxin pex6p; pex61.60.0009
7AJ010482_1Myopodin protein; myopodin2.10.001
8XM_092643_1Similar to b29 protein; loc1655241.90.001
9AK075317_1cDNA clone moderately similar to Mus musculus gng3lg mRNA; unnamed protein product2.10.001
10AB062787_1Triggering receptor trem-2v2.30.0011
11AY014403_1Kinesin-like protein rbkin1; rbkin1.50.0013
12AF241254_1Angiotensin converting enzyme-like protein1.80.0016
13XM_070666_1Similar to junctophilin 1; mitsugumin72; junctophilin type1; jph12.10.0017
14XM_171974_1Similar to zinc finger protein 91 (hpf7; htf10); loc2566961.70.0018
15BC028101_1Bruno-like 5; RNA-binding protein (drosophila)1.50.0019
16XM_063253_1Similar to NADH dehydrogenase (ubiquinone) 1 alpha subcomplex; 4; loc1226672.10.0021
17XM_058961_1Similar to riken cDNA 4021401a16; loc1260031.60.0026
18XM_167626_1Hypothetical protein xp_167626; loc2209321.60.0027
19NM_139120_1yy1-associated protein; isoform 4; yap1.50.0031
20AK022552_1cDNA clone highly similar to Rattus norvegicus rexo70 mRNA; unnamed protein product.1.50.0031
21XM_106383_1Hypothetical protein xp_106383; loc1669441.80.0031
22AK097855_1cDNA clone unnamed protein product1.60.0032
23AK074215_1cDNA clone unnamed protein product1.50.00324
24AK074686_1cDNA clone unnamed protein product1.60.0036
25XM_067012_1Similar to ptpn13-like; y-linked; testis-specific PTP-BL-related protein on y; loc1400161.60.0041
26XM_170930_1Similar to dj830a10.1 (ecotropic viral integration site 5); loc2559781.60.0045
27XM_171784_1Similar to cg15057 gene product; loc25631320.0047
28XM_167035_1Similar to heparan sulfate d-glucosaminyl 3-o-sulfotransferase 1 precursor; heparin-glucosamine 3-o-sulfotransferase; loc2225371.60.0047
29XM_115902_1Similar to poly(a) binding protein; cytoplasmic 1; loc2070611.50.0053
30AK091802_1cDNA clone unnamed protein product.1.60.0053
31XM_097203_1Hypothetical protein xp_097203; loc1471571.50.0053
32BC028048_1Unknown (protein for mgc:40108)1.60.0058
33XM_166973_1Similar to b24o18.3 (pom121 membrane glycoprotein (rat homolog)-like 2); loc2195491.50.0058
34AK056874_1cDNA clone unnamed protein product.1.70.0062
35XM_064853_1Similar to zinc finger protein 347; zinc finger 1111; loc1258911.60.0066
36XM_119769_1Hypothetical protein xp_119769; loc2054051.60.0066
37AL138875_3ba103j18.1.2 (novel protein; isoform 2); ba103j18.11.80.0067
38BC012183_1Unknown (protein for mgc:20470)1.70.0074
39XM_065532_1Similar to hypothetical protein flj13725; kiaa1930 protein; loc1300171.50.0075
40XM_032161_1Hypothetical protein xp_032161; loc904941.70.0079
41XM_033004_1Hypothetical protein bc005107; loc906251.80.0083
42XM_090444_1Similar to synaptotagmin 10; loc1606991.60.0085
43AK091473_1cDNA clone unnamed protein product20.0086
44XM_166111_1Similar to snap-25-interacting protein; loc2196720.50.01
45AL035464_1dj1043e3.1 (novel protein); dj1043e3.11.60.0111
46AK026702_1Homo sapiens cDNA: flj23049 fis; clone lng02559; unnamed protein product20.0112
47AB014569_1kiaa0669 protein; kiaa06690.40.0126
48BC030602_1Similar to myosin IC1.80.0126
49AB062487_1ok/sw-cl.68; ok/sw-cl.681.60.0134
50AF123074_1Cytoplasmic dynein intermediate chain 11.80.0139
51BC034327_1Similar to kiaa1683 protein1.80.0160
52NM_002258_1Killer cell lectin-like receptor subfamily b; member 1; klrb11.50.0167
53AF254067_1Interleukin 21 receptor; IL21R1.60.0198
54AF230904_1c-Cbl-interacting protein; cin850.50.0201
55XM_096879_1Hypothetical protein xp_096879; loc1458281.60.0212
56NM_001813_1Centromere protein e; CENPE2.50.0212
57XM_173595_1Hypothetical protein xp_173595; loc2542340.40.0213
58BC009870_1Gamma tubulin ring complex protein (76p gene)1.50.0226
59XM_045632_1Similar to hypothetical protein flj11292; loc925391.50.0227
60XM_116109_1Similar to cg1364 gene product; loc2016152.20.0229
61AK091107_1cDNA clone unnamed protein product.0.40.0252
62XM_171089_1Similar to nephronectin; loc2557431.60.0255
63XM_170392_1Similar to beta-1;3-galactosyl-o-glycosyl-glycoprotein beta-1;6-n-acetylglucosaminyltransferase (core 2 branching enzyme) (core2-glcnac-transferase) (c2gnt) (core 2 gnt); loc2231011.70.0277
64XM_167601_1Similar to knockout; loc2197351.50.0306
65AF269161_1c21orf7 form a1.60.0311
66XM_058513_1Similar to riken cDNA 4921513o20; loc1208921.50.0320
67XM_071224_1Similar to putative gene with similarity to zinc finger proteins; loc1401601.60.0321
68BC020955_1Similar to hypothetical protein flj110461.70.0323
69BC031660_1Similar to loc1660751.80.0336
70NM_015847_1Methyl-cpg binding domain protein 1; isoform pcm1; mbd11.60.0339
71XM_066779_1Similar to sarcoma antigen; putative tumor antigen; loc1395871.60.0341
72BC004957_1Similar to riken cDNA 1600014c10 gene0.50.0345
73BC012184_1Unknown (protein for mgc:20471)1.70.0347
74AK095926_1cDNA clone unnamed protein product.1.50.0373
75XM_067647_1Similar to 60s ribosomal protein l23a; loc1320661.60.0383
76BC015338_1Unknown (protein for mgc:21282)1.70.0383
77XM_166207_1Similar to riken cDNA 2 410 018 m14; loc2195411.60.0388
78XM_094365_1Similar to early b-cell factor (olfactory neuronal transcription factor 1); loc1672521.50.0392
79D01038_1vla-3 alpha subunit1.50.0393
80BC007653_1Unknown (protein for image:3610013)1.60.0399
81NM_022442_1Ubiquitin-conjugating enzyme e2 variant 1; isoform c; ube2v11.60.0409
82AF268387_1Laryngeal carcinoma-related protein 11.60.0416
83XM_168471_1Hypothetical protein xp_168471; loc2221821.50.0426
84XM_088886_1Similar to c4b-binding protein alpha chain precursor (c4bp) (proline-rich protein) (prp); loc1634261.70.0430
85XM_116262_1Similar to platelet basic protein precursor (PBP) (small inducible cytokine b7) (cxcl7); loc2019600.40.0431
86XM_097883_1Hypothetical protein xp_097883; loc1502731.70.0440
87XM_118021_1Hypothetical protein xp_118021; loc2037661.50.0441
88AK001268_1cDNA clone unnamed protein product1.80.0447
89NM_139238_1adam-ts-related protein 1; isoform 1; adamtsl11.50.0471
90AF116720_1pro30151.60.0487
91AF319633_1Putative potassium channel kiaa00271.70.0490

GenBank identity number (ID) and FC in gene expression are also displayed.

We first confirmed by qRT-PCR the microarray result and further assessed FXN and HAX-1 protein levels in FXN cells and EMPTY cells (Fig. 1A).

HAX-1 expression is regulated by FXN levels. Overexpression of FXN upregulates HAX-1 in GM15850 FRDA patient-derived B cells (A) and in HEK293 cells (B). (A) Left panels: mRNA relative quantity was analyzed in immortalized GM15850 FRDA patient-derived B cells stably reconstituted with empty vector (EV) and wild-type frataxin (FXN) by qRT-PCR using the housekeeping invariant reference gene TUBULIN. Values are means ± SEM (n = 2). Center panel: Expression of FXN, HAX-1 and Tubulin as loading control was analyzed by western blot. Data are representative of two independent experiments. Right panels: Densitometric quantification. FXN and HAX-1 protein expression were normalized with Tubulin. Data represent the mean ± SEM of two independent experiments. (B) Left panels: mRNA level was analyzed in HEK293 cells stably reconstituted with empty vector (EV) and wild-type frataxin (FXN) by qRT-PCR using the housekeeping invariant reference gene TUBULIN. Values are means ± SEM (n = 2). Center panel: Expression of FXN, HAX-1 and Tubulin as loading control was analyzed by western blot. Data are representative of two independent experiments. Right panels: Densitometric quantification. HAX-1 and FXN protein expression were normalized with Tubulin. Data represent the mean ± SEM (n = 2). (C). HEK293 cells were transiently transfected with plasmid for FXN gene interference (shFXN, +) or empty vector (−) every 2 days. ATP synthase (ATP S.), FXN and HAX-1 were analyzed after the fourth (IV) round of transfection. Data are representative of 3 independent experiments. (D) FXN and HAX-1 expression analyzed in C were normalized with ATP synthase. Values are means ± SEM (n = 3). P-values were calculated with Student’s t-test (*P < 0.05; **P < 0.01, ****P < 0.0001).
Figure 1

HAX-1 expression is regulated by FXN levels. Overexpression of FXN upregulates HAX-1 in GM15850 FRDA patient-derived B cells (A) and in HEK293 cells (B). (A) Left panels: mRNA relative quantity was analyzed in immortalized GM15850 FRDA patient-derived B cells stably reconstituted with empty vector (EV) and wild-type frataxin (FXN) by qRT-PCR using the housekeeping invariant reference gene TUBULIN. Values are means ± SEM (n = 2). Center panel: Expression of FXN, HAX-1 and Tubulin as loading control was analyzed by western blot. Data are representative of two independent experiments. Right panels: Densitometric quantification. FXN and HAX-1 protein expression were normalized with Tubulin. Data represent the mean ± SEM of two independent experiments. (B) Left panels: mRNA level was analyzed in HEK293 cells stably reconstituted with empty vector (EV) and wild-type frataxin (FXN) by qRT-PCR using the housekeeping invariant reference gene TUBULIN. Values are means ± SEM (n = 2). Center panel: Expression of FXN, HAX-1 and Tubulin as loading control was analyzed by western blot. Data are representative of two independent experiments. Right panels: Densitometric quantification. HAX-1 and FXN protein expression were normalized with Tubulin. Data represent the mean ± SEM (n = 2). (C). HEK293 cells were transiently transfected with plasmid for FXN gene interference (shFXN, +) or empty vector (−) every 2 days. ATP synthase (ATP S.), FXN and HAX-1 were analyzed after the fourth (IV) round of transfection. Data are representative of 3 independent experiments. (D) FXN and HAX-1 expression analyzed in C were normalized with ATP synthase. Values are means ± SEM (n = 3). P-values were calculated with Student’s t-test (*P < 0.05; **P < 0.01, ****P < 0.0001).

Furthermore, FXN and HAX-1 expression were analyzed both at mRNA and protein levels in HEK293 stably transfected with empty vector or wild-type FXN. Overexpression of FXN increases HAX-1 both at mRNA and protein levels (Fig. 1B). Conversely, overexpression of HAX-1 did not alter FXN levels (Supplementary Material, Fig. S1).

To further address this relationship, we also interfered with FXN expression using a shRNA-based approach in HEK293 cell line achieving a 55–60% FXN knockdown after four rounds of transient transfection. FXN silencing could reduce HAX-1 expression up to 34% (Fig. 1C and D).

Modulating FXN levels in cardiomyocytes regulate HAX-1 protein levels and their sensitivity to H2O2 treatment

Considering that the heart represents one of the most affected tissues in Friedreich’s ataxia and that HAX-1 is involved in cardioprotection, we subsequently analyzed the association between FXN and HAX-1 protein levels in human cardiac cells. AC16 cardiomyocytes were transiently transfected with wild-type FXN or empty vector. Overexpression of FXN results in a significant 2-fold upregulation of HAX-1 expression (Fig. 2A and B). Moreover, FXN silencing shows that a reduction of FXN protein levels after four rounds of ShFxn plasmid transfection results in decreased HAX-1 expression of approximately 55% (Fig. 2C and D). These data suggest that the coregulation of FXN and HAX-1 is present also in human cardiomyocytes, thus evoking a common pathway active in the heart.

Modulating frataxin levels in cardiomyocytes regulate HAX-1, Nrf2 and MnSOD protein levels and their sensitivity to H2O2 treatment. (A) AC16 cardiac cells were transiently transfected with pIRES2-FXN (FXN) or empty vector (EV). Cells extracts were collected 24- and 72-h post-transfection. Representative blot and corresponding stain-free gel used for FXN and HAX-1 protein (at 72 h) normalization of three independent experiments are shown. (B) Nrf2 (24 h) and MnSOD (72 h) were normalized with ATP synthase (ATP S.). FXN and HAX-1 expression analyzed in A were normalized using stain-free technology. Values are means ± SEM (n = 3). (C) AC16 cardiac cells were transiently transfected with plasmid for FXN gene interference (shFXN, +) or empty vector (−) every 2 days. FXN, HAX-1, Nrf2 and MnSOD were analyzed after the fourth (IV) round of transfection. Representative blot and corresponding stain-free gel used for FXN and HAX-1 protein normalization of three independent experiments are shown. (D) Nrf2 and MnSOD were normalized with ATP synthase (ATP S.). FXN and HAX-1 expression analyzed in (C) were normalized with using stain-free technology. Values are means ± SEM (n = 3). (E) AC16 cardiac cells were transiently transfected with plasmid for frataxin gene interference (shFXN) or empty vector (pSUPER) each 2 days. After three rounds of transfections, AC16 were additionally transfected with empty vector pcDNA3.1 or HAX-1. At 24 h post transfection, cells were treated with 0.5 mm of H2O2 for 2 h. Cell viability was measured by countess staining selectively the dead cells with Trypan Blue. Relative cell viability was expressed as mean ratio of the number of living cells in H2O2-treated sample versus the number of cells seeded. Values are means ± SEM (n = 2). P-values were calculated with Student’s t-test (*P < 0.05; **P < 0.01).
Figure 2

Modulating frataxin levels in cardiomyocytes regulate HAX-1, Nrf2 and MnSOD protein levels and their sensitivity to H2O2 treatment. (A) AC16 cardiac cells were transiently transfected with pIRES2-FXN (FXN) or empty vector (EV). Cells extracts were collected 24- and 72-h post-transfection. Representative blot and corresponding stain-free gel used for FXN and HAX-1 protein (at 72 h) normalization of three independent experiments are shown. (B) Nrf2 (24 h) and MnSOD (72 h) were normalized with ATP synthase (ATP S.). FXN and HAX-1 expression analyzed in A were normalized using stain-free technology. Values are means ± SEM (n = 3). (C) AC16 cardiac cells were transiently transfected with plasmid for FXN gene interference (shFXN, +) or empty vector (−) every 2 days. FXN, HAX-1, Nrf2 and MnSOD were analyzed after the fourth (IV) round of transfection. Representative blot and corresponding stain-free gel used for FXN and HAX-1 protein normalization of three independent experiments are shown. (D) Nrf2 and MnSOD were normalized with ATP synthase (ATP S.). FXN and HAX-1 expression analyzed in (C) were normalized with using stain-free technology. Values are means ± SEM (n = 3). (E) AC16 cardiac cells were transiently transfected with plasmid for frataxin gene interference (shFXN) or empty vector (pSUPER) each 2 days. After three rounds of transfections, AC16 were additionally transfected with empty vector pcDNA3.1 or HAX-1. At 24 h post transfection, cells were treated with 0.5 mm of H2O2 for 2 h. Cell viability was measured by countess staining selectively the dead cells with Trypan Blue. Relative cell viability was expressed as mean ratio of the number of living cells in H2O2-treated sample versus the number of cells seeded. Values are means ± SEM (n = 2). P-values were calculated with Student’s t-test (*P < 0.05; **P < 0.01).

FRDA-derived cells have been reported to have disabled antioxidant responses such as the ones mediated by MnSOD (manganese-dependent superoxide dismutase) (19,20) and Nrf2 (nuclear factor erythroid derived 2-like 2) (21). We therefore analyzed whether these antioxidant proteins could be regulated by FXN modulation in cardiomyocytes. Indeed, upon FXN overexpression, HAX-1, Nrf2 and MnSOD levels are increased. Intriguingly, Nrf2 upregulation anticipates the increase of HAX-1 levels (Fig. 2A and B). Silencing of FXN upon four rounds of ShFxn plasmid transfection also resulted in a decreased expression of 57% of Nrf2 and 30% of MnSOD levels (Fig. 2C and D).

We then analyzed the antioxidant response of cardiomyocytes upon treatment with H2O2 evaluating whether HAX-1 transfection following FXN silencing could affect cell survival. Interestingly, we observed that HAX-1 overexpression could compensate the toxicity of H2O2 treatment in cardiomyocytes in which FXN was silenced, thus suggesting that HAX-1 can hamper the oxidative stress in FXN-deficient cells (Fig. 2E).

Low levels of FXN in FRDA-derived cell lines and PBMCs correspond to reduced levels of HAX-1

To corroborate the link between FXN and HAX-1 in FRDA cells, their expression level was analyzed in 11 FXN-deficient lymphoblastoid cell lines derived from FRDA patients and their unaffected carrier relatives. A significant decrease of HAX-1 both at mRNA and protein levels was confirmed in FRDA cell lines (Fig. 3).

Low levels of FXN in FRDA cell lines correspond to reduced levels of HAX-1. FXN and HAX-1 mRNA and protein levels were analyzed in 11 lymphoblastoid cell lines derived from FRDA patients compared to 11 clinically unaffected heterozygous relatives. The mean ratio (Patients/Controls) is illustrated. (A) FXN and HAX-1 mRNA expression (2-ΔCt) analysis was performed with one sample t-test (*P < 0.05, ****P < 0.0001), testing the null hypothesis of a mean = 1. Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. (B) FXN and HAX-1 protein expression were normalized with ATP synthase. Values are means of independent experiments (n = 3). Both overall mean and data range are illustrated. Analysis was performed with one sample t-test (*P < 0.05, ****P < 0.0001), testing the null hypothesis of a mean = 1.
Figure 3

Low levels of FXN in FRDA cell lines correspond to reduced levels of HAX-1. FXN and HAX-1 mRNA and protein levels were analyzed in 11 lymphoblastoid cell lines derived from FRDA patients compared to 11 clinically unaffected heterozygous relatives. The mean ratio (Patients/Controls) is illustrated. (A) FXN and HAX-1 mRNA expression (2-ΔCt) analysis was performed with one sample t-test (*P < 0.05, ****P < 0.0001), testing the null hypothesis of a mean = 1. Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. (B) FXN and HAX-1 protein expression were normalized with ATP synthase. Values are means of independent experiments (n = 3). Both overall mean and data range are illustrated. Analysis was performed with one sample t-test (*P < 0.05, ****P < 0.0001), testing the null hypothesis of a mean = 1.

Subsequently, we obtained and assessed baseline data for 53 patients with Friedreich’s ataxia [27 (51%) females and 26 (49%) males], with ages ranging from 20 to 72 years (mean 39 years ±12). Fifty of 53 patients (94%) were homozygous for expanded GAA repeats in FXN gene, with the larger allele containing at least 200 GAA triplets (Table 2); the remaining 3 patients (6%) were compound heterozygous, containing an expanded GAA repeat on one allele and an FXN point mutation on the other. We excluded these latter from further subgroup expression analyses. Twenty-two patients (44%) had early-onset, 16 (32%) intermediate-onset and 12 (24%) late-onset disease (22). Twenty patients (38%) developed a hypertrophic cardiomyopathy (Table 2 and Supplementary Material, Table S2).

Table 2

Characteristics of FRDA patients

FRDA patients (N)53
Sex (F/M)27 (51%)/26 (49%)
Age (mean/range)41 years (20–72)
Expanded GAA repeats in the larger allele (mean/range)780 (200–1200)
Cardiac disease (N/%)20 (38%)
FRDA patients (N)53
Sex (F/M)27 (51%)/26 (49%)
Age (mean/range)41 years (20–72)
Expanded GAA repeats in the larger allele (mean/range)780 (200–1200)
Cardiac disease (N/%)20 (38%)
Table 2

Characteristics of FRDA patients

FRDA patients (N)53
Sex (F/M)27 (51%)/26 (49%)
Age (mean/range)41 years (20–72)
Expanded GAA repeats in the larger allele (mean/range)780 (200–1200)
Cardiac disease (N/%)20 (38%)
FRDA patients (N)53
Sex (F/M)27 (51%)/26 (49%)
Age (mean/range)41 years (20–72)
Expanded GAA repeats in the larger allele (mean/range)780 (200–1200)
Cardiac disease (N/%)20 (38%)

In order to evaluate HAX-1 expression as a potential biomarker in FRDA, FXN and HAX-1 expression were analyzed in PBMCs from these FRDA patients and non-related healthy controls. For mRNA expression analysis, values were available for 39 patients (74%, mean age 42 years ±13) and 23 non-related healthy controls (mean age 41 years ±13). Data for protein expression were available for 41 patients (77%, mean age 39 years ±13) and 27 non-related healthy controls (mean age 41 years ±12). We observed that FXN and HAX-1 expression are coregulated, both at mRNA (Fig. 4A and B) and protein levels (Fig. 4D and E).

FRDA PBMCs express lower levels of HAX-1. FXN and HAX-1 expression were analyzed in PBMCs derived from FRDA patients (Patients) and healthy individuals who did not exhibit any type of heart problems (Controls). mRNA expression was normalized with ATP SYNTHASE (2-△Ct) in (A, B) Patients (n = 39) and Controls (n = 23). Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. FXN and HAX-1 protein expression were normalized with ATP Synthase in (D, E) Patients (n = 41) and Controls (n = 27). Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. Scatter plot showing Frataxin (FXN) versus HAX-1 mRNA (C) and protein (F) values across all subjects. Dashed line: Fitted linear regression model. R2: R squared value of the regression model. r = Pearson correlation. P = P-value related to the slope of the regression model. (G) FXN and HAX-1 mRNA levels were analyzed in 13 FRDA patients with hypertrophic cardiomyopathy (HCM), 26 FRDA patients without hypertrophic cardiomyopathy (w/o HCM) and 23 healthy individuals who did not exhibit any type of heart problems (Controls). Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. (H) FXN and HAX-1 protein levels were analyzed in 18 FRDA patients with hypertrophic cardiomyopathy (HCM), 23 FRDA patients without hypertrophic cardiomyopathy (w/o HCM) and 27 healthy individuals who did not exhibit any type of heart problems (Controls). Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. Analysis was performed with Student’s t-test (**P < 0.01, ***P < 0.001, ****P < 0.0001).
Figure 4

FRDA PBMCs express lower levels of HAX-1. FXN and HAX-1 expression were analyzed in PBMCs derived from FRDA patients (Patients) and healthy individuals who did not exhibit any type of heart problems (Controls). mRNA expression was normalized with ATP SYNTHASE (2-△Ct) in (A, B) Patients (n = 39) and Controls (n = 23). Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. FXN and HAX-1 protein expression were normalized with ATP Synthase in (D, E) Patients (n = 41) and Controls (n = 27). Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. Scatter plot showing Frataxin (FXN) versus HAX-1 mRNA (C) and protein (F) values across all subjects. Dashed line: Fitted linear regression model. R2: R squared value of the regression model. r = Pearson correlation. P = P-value related to the slope of the regression model. (G) FXN and HAX-1 mRNA levels were analyzed in 13 FRDA patients with hypertrophic cardiomyopathy (HCM), 26 FRDA patients without hypertrophic cardiomyopathy (w/o HCM) and 23 healthy individuals who did not exhibit any type of heart problems (Controls). Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. (H) FXN and HAX-1 protein levels were analyzed in 18 FRDA patients with hypertrophic cardiomyopathy (HCM), 23 FRDA patients without hypertrophic cardiomyopathy (w/o HCM) and 27 healthy individuals who did not exhibit any type of heart problems (Controls). Values are means of independent experiments (n = 2–5). Both overall mean and data range are illustrated. Analysis was performed with Student’s t-test (**P < 0.01, ***P < 0.001, ****P < 0.0001).

Regression analysis showed a statistically significant association between FXN and HAX-1 both at mRNA and protein levels (Fig. 4C and F). In particular, when analyzing a possible mRNA-level association, we found a statistically significant, positive relationship between FXN and HAX-1 (R2 = 0.55, P < 0.05, Pearson r = 0.54) (Fig. 4C). This association was confirmed, with an even higher effect size (i.e. correlation), at protein level, where we again found a statistically significant, positive relationship between FXN and HAX-1 (model R2 = 0.6, P < 0.001, Pearson r = 0.81) (Fig. 4F). The difference of FXN and HAX-1 expression in FRDA patients with and without hypertrophic cardiomyopathy is not statistically significant, although the HAX mRNA expression is lower in FRDA patients with hypertrophic cardiomyopathy compared to healthy controls (Fig. 4G and H).

We also analyzed whether these FRDA-derived PBMCs could have altered expression of antioxidant enzymes MnSOD and Nrf2. A significant difference was observed only for MnSOD protein expression, which is expressed at lower levels in FRDA patients compared to healthy individuals (Supplementary Material, Fig. S2A). In addition, we found a statistically significant, positive relationship between FXN and Nrf2 (P < 0.05, Spearman r = 0.38) as well as between HAX-1 and Nrf2 (P < 0.01, Spearman r = 0.41, Supplementary Material, Fig. S2B).

Discussion

This study shows for the first time a positive correlation between FXN and HAX-1 expression both at protein and mRNA levels in FRDA. Interestingly, low levels of FXN in both FRDA cell lines and PBMCs of FRDA patients correspond to reduced levels of HAX-1.

Cardiac dysfunction may develop early in the course of FRDA and is recognized as the leading cause of death in patients (23). Both FXN and HAX-1 are crucial for cell survival. Indeed, FXN KO in mice is lethal (24) and overexpression of FXN in human cells protects them from apoptotic stimuli (25). Conversely, HAX-1 is highly expressed in the heart and is involved in protection of cardiomyocytes from injury (8). Cardiomyocytes are extremely sensitive to hypoxia and subsequent oxidative stress-induced damage. It is noteworthy that HAX-1 increases in hypoxic environment (26) as well as FXN that indeed participates in the stress response of tumor adaptation to hypoxia (27). Furthermore, under oxidative stress conditions, the correct assembling of actin fibers is impaired in FRDA patients thus preventing the translocation of nuclear factor (erythroid derived 2)-like 2 (Nrf2) transcription factor into the nucleus and consequently hampering the antioxidative responses (28). Moreover, HAX-1 downregulation in different types of cells results in increased apoptosis due to oxidative stress (17,29,30). We have observed that modulation of FXN in AC16 cardiomyocytes regulates consequently HAX-1 levels but also Nrf2 and MnSOD antioxidant protein levels. All these proteins are upregulated upon overexpression of FXN or downregulated upon FXN silencing. Interestingly, we observed that HAX-1 overexpression could compensate for the toxicity of H2O2 treatment in cardiomyocytes in which FXN was silenced. Therefore, HAX-1 upregulation could rescue the impaired antioxidant cellular responses caused by FXN deficiency. The linked expression of FXN, HAX-1 and antioxidant proteins MnSOD and Nrf2 was also verified ex vivo in PBMCs. Although we could only detect statistically significant differences in MnSOD expression between healthy controls and FRDA patients, an interesting correlation between Nrf2-FXN-HAX-1 was observed (Supplementary Material, Fig. S2), underlining the already known importance of antioxidant defects in FRDA, and especially because Nrf2 is considered a therapeutic target for this disease (31,32).

In addition, since in vivo data on rat models and in vitro overexpression experiments suggest an antagonistic role for HAX1 variant II (HAX-1 v4) (10), we also performed a quantitative analysis of this proapoptotic HAX1 variant in all FRDA cells previously analyzed for HAX-1 v1 levels. However, both in healthy controls and FRDA cells, HAX-1 v4 mRNA expression is about 10-fold less than variant v1 (Supplementary Material, Fig. S3). Finally, HAX1 v1/HAX-1 v4 mRNA expression ratio is quite similar in control and FRDA cells (Supplementary Material, Fig. S3). Our data therefore do not support the hypothesis of an imbalance between these two isoforms as the major cause of apoptosis modulation and cell survival due to FXN deficiency.

As HAX-1 is required for the survival of cerebellar neurons (7) and involved in the spinocerebellar ataxia 13 through a physical interaction with KV3.3 channels (9), we therefore also investigated whether a direct interaction between HAX-1 and FXN would explain the pathogenic mechanism in FRDA. However, we could not observe HAX-1/FXN interactions neither in HEK293 cells nor in AC16 cardiomyocytes (Supplementary Material, Fig. S4). Hence, all together these data suggest that FXN could contribute to regulate the cellular oxidative resistance by modulating HAX-1 levels, without a direct interaction between these proteins.

Considering that both FXN and HAX-1 protect from apoptotic stimuli and that dysregulated apoptosis underlies the progression of cardiomyopathies and neurodegeneration, low levels of FXN and consequently of HAX-1 could contribute to the development of hypertrophic cardiomyopathy as well as neuronal deficit, important features in FRDA. Interestingly, in this regard, several microRNAs have been described as modulators of FXN and putative biomarkers for cardiomyopathy (33–38). Further investigation would be necessary to clarify whether and which specific epigenetic mechanisms could coordinate FXN and HAX-1 expression in neurons.

The identification of new disease biomarkers associated to cardiac alteration could be important to define a risk prediction and reduce morbidity and mortality. Additional analyses of other diagnostic features of cardiac disease in a larger group of FRDA patients would allow to define HAX-1 as a potential prognostic biomarker, when found associated with clinical benefit. Finally, it also warrants further investigation to evaluate its use as a possible therapeutic target of cardiac disease.

Materials and Methods

DNA constructs

The construct pIRES2-FXN(1–210) containing human FXN cDNA cloned into the bicistronic expression vector pIRES2-EGFP (Clontech Laboratories) and the shRNA construct (shFxn) were generated in this laboratory as previously reported (25,27). The construct pcDNA3.1 + N-HA-HAX-1 v1 (clone ID: OHu19870) was provided by GenScript (Piscataway, NJ, USA).

Cell cultures and transfections

Human embryonic kidney cells (HEK-293 Flp-In) stably expressing FXN(1–210) were previously described (39) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). AC16 human cardiomyocyte cell line (Merck Millipore, CA, USA) were cultured in DMEM-F12 medium supplemented with 12.5% FBS.

To overexpress the wild-type FXN and HAX-1 v1, AC16 cardiac cells were respectively transfected with pIRES2-FXN and pcDNA3.1 + N-HA-HAX-1 v1 using Lipofectamine 2000 (Invitrogen), following the manufacturer’s instructions.

To interfere with FXN expression, HEK-293 cells and AC16 cardiac cells were transfected with shRNA plasmid for FXN gene (shFXN) using Lipofectamine 2000 (Invitrogen), following the manufacturer’s instructions. Four rounds of transfection of HEK-293 cells every 2 days were performed to achieve a 55–60% FXN knockdown, and AC16 cardiac cells were transfected until four rounds of transfection to achieve a 55% of FXN reduction.

Immortalized GM16798, GM16223, GM16216, GM16228, GM14518, GM16210, GM16214, GM16203, GM16243, GM16205 and GM15850 FRDA patient-derived B cells and immortalized GM16241, GM16236, GM16213, GM16229, GM14519, GM16212, GM16215, GM16202, GM16237, GM16239 and GM15849 lymphoblasts from clinically unaffected heterozygous parents were obtained from NIGMS Human Genetic Cell Repository, Coriell Institute for Medical Research (Camden, NJ, USA) and cultured in RPMI 1640 supplemented with 15% FBS.

Measurement of cell proliferation and viability using cell counting

For cell viability assay, AC16 cardiac cells were transiently transfected with plasmid for frataxin gene interference (shFXN) or empty vector (pSUPER) each 2 days. After three rounds of transfections, AC16 were additionally transfected with empty vector pcDNA3.1 or pcDNA3.1 + N-HA-HAX-1 v1. 24 h post transfection, 1.4 × 105 cells were seeded in 12-well plates and then treated with 0.5 mm of H2O2 for 2 h. Cell viability was measured by Countess Automated Cell Counter (Thermo Fisher Scientific) staining selectively the dead cells with Trypan Blue.

Microarray analysis and processing

Total RNA of GM15850 FRDA patient-derived B cells stably reconstituted either with empty vector or FXN was extracted and purified using TriZol reagent (Thermo Fisher Scientific). RNA quality and quantity was assessed using a Nanodrop spectrophotometer (Thermo Scientific) and agarose gel electrophoresis. Methods for sample processing and microarray experiments have been previously described (40). Briefly, direct labeling of second strand (ss) cDNA was conducted according to manufacturer’s instructions (Invitrogen) with starting material of 20 μg of total RNA. The amino-allyl labeled dNTP mix was added to the reaction to generate amino-allyl-labeled ss cDNA. PCR purification kit (Qiagen) was used to remove unincorporated dNTPs, fluorescent dyes and primer. Alexa555- and Alexa647-labeled cDNA was then combined in one tube and evaporated almost to dryness. The combined labeled cDNAs were stored on ice protected from light until hybridization. Hybridization was performed in duplicate, with one dye swap and slides were incubated in a water bath at 42°C for an overnight in the dark.

We used the Human 40K A OciChip™ array, consisting of 20 000 genes with full functional characterization and content referencing and the Human 40K B OciChip™ array consisting of genes referenced against several NCBI databases (www.ocimumbio.com). Each slide was scanned on the GenePix 4000B Microarray Scanner at the optimal wavelength for the Alexa555 (F532) and Alexa647 (F635) dyes. Each spot was automatically segmented; total intensities as well as the fluorescence ratios of the two dyes for each spot were then calculated. The spots were flagged when they exhibited poor hybridization signals and when they were saturated (F635 or F532 median = 65 535). Flagged spots were filtered and systematic bias in the data was removed by applying dye-swap and printiploess intra-array normalization followed by inter-array quantile normalization. Dye-swap normalization makes use of the reverse labeling in the two microarray replicates directly (41). To establish the significance of observed regulation for each gene, we used one sample t-test. Finally, only genes with a satisfactory effect (FC ≥ ±1.5) were considered. The expression data of microarray experiments are available as a specific GEO Sample record and may be linked as follows: http://www.ncbi.nlm.nih.gov/geo/query/GSE108200.

FRDA patient enrollment and characteristics

FRDA patients were recruited from three different centers: University of Rome ‘Tor vergata’, Sapienza University of Rome and Istituto Neurologico Carlo Besta. Inclusion criteria were (a) genetic diagnosis of FRDA, (b) age ≥ 18 years and (c) available echocardiography and electrocardiogram evaluations. Exclusion criteria were the presence of active substance abuse, hematological disorders or major comorbidities requiring chronic pharmacological treatment, not related to FRDA. All the enrolled patients gave informed consent prior to the inclusion in the study. The investigation is conformed to the principles outlined in the Declaration of Helsinki and approval was granted by Institutional Ethics Committee (n.47/16 and n.56).

Isolation of mononuclear cells from peripheral blood

PBMCs from FRDA patients and healthy individuals were isolated using density-gradient medium. For western blot analysis, fresh blood was diluted in equal volume of PBS, gently layered over top of the Lympholyte (Lympholyte-H; Cedarlane Laboratories) and then centrifuged at 750g for 30′ at room temperature (RT) without brake. The enriched mononuclear cell layer was pipetted off in a new tube and washed two times with PBS. To remove the contaminating red blood cells, the cell pellet was resuspended in 2 ml of ACK lysing buffer (Lonza). Cells were incubated at RT for 5′, gently mixed every minute, then centrifuged at 300g for another 5′ and subsequently washed three times with PBS.

For RNA expression analysis, fresh blood was gently layered on equal volume of Ficoll-Paque PLUS (GE Healthcare) and then centrifuged at 400g for 40′ at RT without brake. The mononuclear cell layer was transferred in a new tube and washed two times with PBS. The cell pellet was resuspended in 1 ml of TRIzol (Thermo Fisher Scientific).

Western blot analysis

Total cell extracts were prepared in ice-cold modified RIPA buffer (10 mmol/l sodium phosphate, pH 7.2, 150 mmol/l NaCl, 1% Na deoxycholate, 0.1% SDS, 1% Igepal CA-630 and 2 mmol/L EDTA) or IP buffer (50 mmol/l Tris–HCl, pH 7.5, 150 mmol/l NaCl, 1% Igepal CA-630, 5 mmol/l EDTA, 5 mmol/l EGTA) supplemented with complete protease inhibitor cocktail (Roche Diagnostics, Milan, Italy). About 50 or 100 μg of the total cell lysates were resolved by SDS-PAGE and analyzed by immunoblot with specific mAb anti-frataxin (Abcam, ab110328), mAb anti-HAX-1 (BD Biosciences, 610 825), mAb anti-Nrf2 (Abcam, ab62352), pAb anti-MnSOD (Enzo Life Science), mAb anti-ATP synthase β (BD Biosciences, 612 519), mAb anti-Tubulin (Sigma, T9026) and secondary antibody horseradish peroxidase-conjugated goat anti-mouse (Pierce) using ECL system detection (GE Healthcare Europe GmbH, Milan, Italy). Densitometric analyses were performed using ImageLab software (Biorad). FXN and HAX-1 protein quantification on AC16 human cardiomyocyte cell line was carried out using stain-free technology (42), where the volume density of each target protein band was normalized to the total protein loaded into each lane using ImageLab software (Biorad).

Quantitative RT-PCR analysis

Total RNA was extracted from HEK-293 Flp-In cells, immortalized B cells and PBMCs using TRIzol reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions. Then, 1.5 μg of total RNA was retrotranscribed in cDNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher) according to the manufacturer’s instructions. Primers to quantify mRNA expression were designed to span exon/intron junctions to avoid amplification of genomic DNA by using Primer blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast). The primers sequences were as follows: FXN-Fw: 5′-CACCCAGGCTCTCTAGATG-3′ and FXN-Rev: 5’-CACCACTCCCAAAGGAGAC-3′; HAX1.v1-Fw: 5’-CTGGACCTCGGAGCCACAGA-3′ and HAX1.v1-Rev: 5’-GTTCCCACGGCCCCATGAG-3′.; α4-TUBULIN-Fw: 5-‘GAGCACTCAGACTGTGCCTT-3′ and Rev: 5’-CGATTGAGGTTGGTGTAGGT-3′; ATP-SYNTHASE-Fw: 5′-CTCAGCCATTCCAGGTTGC-3′ and Rev: 5′-CATATTCACCTGCCAAAATCTG -3′. HAX1 primers were variant-specific for full-length or splice variant 1 (HAX1.v1, NM_006118.3). α4-TUBULIN and ATP-SYNTHASE have been used for data normalization in HEK-293 and GM15850 or immortalized lymphoblasts and PBMC, respectively. Each qRT-PCR analysis has been performed in triplicate for at least two times. To evaluate the expression level of FXN and HAX1.v1 splice variants, the threshold cycle (Ct) values of each sample has been extracted with the Real Time PCR 7500 Software (Applied Biosystems, Waltham, MA, USA). The Ct values express the relative measure of the concentration of an mRNA target in the PCR reaction. The normalization of the Ct values with the Ct of a selected housekeeping gene, allows the calculation of the 2-ΔCt value for each sample. The 2-ΔCt value represents the absolute expression level of the target gene and it is shown in the graphs.

Statistical analysis

Kolmogorov–Smirnov test has been used to analyze the distribution of the data, which are expressed as median and range. For protein analysis, the significance of differences between populations of data was assessed according to the Student’s t-test with a level of significance of at least P ≤ 0.05. For mRNA expression, data from HEK-293, GM15850 and PBMCs were normally distributed so Student’s t-test has been used; for data not normally distributed (immortalized lymphoblasts), Mann–Whitney test for comparisons between two groups has been used. Significance was set at P ≤ 0.05. Statistical analyses were performed using GraphPad Prism ver. 6.0 (GraphPad Software, San Diego, CA, USA).

In order to examine putative associations between frataxin (FXN) versus HAX-1 values, we employed a linear regression model where FXN was modeled as a function of HAX-1 as well as an offset term. The association was considered statistically significant if the P-value associated with the slope of the regression model was P < 0.05. The effect size was further examined through the Pearson correlation coefficient.

Acknowledgements

We thank all colleagues in our laboratory for helpful discussion.

Funding

Non Communicable Disease (NCDS-2013-00000333 to G.N.); European Research Council (Advanced Grant number 293699, FAST to R.T.); National Ataxia Foundation and Mission Sustainability (CARDIMIRAX, CUP: E81I18000370005) to F.M.; Telethon (grant number GGP15004 to I.C.).

Conflict of Interest statement

None declared.

References

1.

Campuzano
,
V.
,
Montermini
,
L.
,
Molto
,
M.D.
,
Pianese
,
L.
,
Cossee
,
M.
,
Cavalcanti
,
F.
,
Monros
,
E.
,
Rodius
,
F.
,
Duclos
,
F.
,
Monticelli
,
A.
et al. (
1996
)
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion
.
Science
,
271
,
1423
1427
.

2.

Tamarit
,
J.
,
Obis
,
E.
and
Ros
,
J.
(
2016
)
Oxidative stress and altered lipid metabolism in Friedreich ataxia
.
Free Radic. Biol. Med.
,
100
,
138
146
.

3.

Lane
,
D.J.
,
Huang
,
M.L.
,
Ting
,
S.
,
Sivagurunathan
,
S.
and
Richardson
,
D.R.
(
2013
)
Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich's ataxia
.
Biochem. J.
,
453
,
321
336
.

4.

Yap
,
S.V.
,
Koontz
,
J.M.
and
Kontrogianni-Konstantopoulos
,
A.
(
2011
)
HAX-1: a family of apoptotic regulators in health and disease
.
J. Cell. Physiol.
,
226
,
2752
2761
.

5.

Farajifard
,
H.
,
Zavvar
,
M.
,
Rajaei
,
T.
,
Noorbakhsh
,
F.
,
Nikougoftar-Zarif
,
M.
,
Azadmanesh
,
K.
,
Kompani
,
F.
and
Rezaei
,
N.
(
2018
)
In vitro study of HAX1 gene therapy by retro viral transduction as a therapeutic target in severe congenital neutropenia
.
Eur. Cytokine Netw.
,
29
,
146
152
.

6.

Lu
,
X.
,
Xue
,
P.
,
Fu
,
L.
,
Zhang
,
J.
,
Jiang
,
J.
,
Guo
,
X.
,
Bao
,
G.
,
Xu
,
G.
,
Sun
,
Y.
,
Chen
,
J.
et al. (
2018
)
HAX1 is associated with neuronal apoptosis and astrocyte proliferation after spinal cord injury
.
Tissue Cell
,
54
,
1
9
.

7.

Chao
,
J.R.
,
Parganas
,
E.
,
Boyd
,
K.
,
Hong
,
C.Y.
,
Opferman
,
J.T.
and
Ihle
,
J.N.
(
2008
)
Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons
.
Nature
,
452
,
98
102
.

8.

Lam
,
C.K.
,
Zhao
,
W.
,
Cai
,
W.
,
Vafiadaki
,
E.
,
Florea
,
S.M.
,
Ren
,
X.
,
Liu
,
Y.
,
Robbins
,
N.
,
Zhang
,
Z.
,
Zhou
,
X.
et al. (
2013
)
Novel role of HAX-1 in ischemic injury protection involvement of heat shock protein 90
.
Circ. Res.
,
112
,
79
89
.

9.

Zhang
,
Y.
,
Zhang
,
X.F.
,
Fleming
,
M.R.
,
Amiri
,
A.
,
El-Hassar
,
L.
,
Surguchev
,
A.A.
,
Hyland
,
C.
,
Jenkins
,
D.P.
,
Desai
,
R.
,
Brown
,
M.R.
et al. (
2016
)
Kv3.3 channels bind Hax-1 and Arp2/3 to assemble a stable local actin network that regulates channel gating
.
Cell
,
165
,
434
448
.

10.

Koontz
,
J.
and
Kontrogianni-Konstantopoulos
,
A.
(
2014
)
Competition through dimerization between antiapoptotic and proapoptotic HS-1-associated protein X-1 (Hax-1)
.
J. Biol. Chem.
,
289
,
3468
3477
.

11.

Hippe
,
A.
,
Bylaite
,
M.
,
Chen
,
M.
,
von Mikecz
,
A.
,
Wolf
,
R.
,
Ruzicka
,
T.
and
Walz
,
M.
(
2006
)
Expression and tissue distribution of mouse Hax1
.
Gene
,
379
,
116
126
.

12.

Han
,
Y.
,
Chen
,
Y.S.
,
Liu
,
Z.
,
Bodyak
,
N.
,
Rigor
,
D.
,
Bisping
,
E.
,
Pu
,
W.T.
and
Kang
,
P.M.
(
2006
)
Overexpression of HAX-1 protects cardiac myocytes from apoptosis through caspase-9 inhibition
.
Circ. Res.
,
99
,
415
423
.

13.

Zhao
,
W.
,
Waggoner
,
J.R.
,
Zhang
,
Z.G.
,
Lam
,
C.K.
,
Han
,
P.
,
Qian
,
J.
,
Schroder
,
P.M.
,
Mitton
,
B.
,
Kontrogianni-Konstantopoulos
,
A.
,
Robia
,
S.L.
et al. (
2009
)
The anti-apoptotic protein HAX-1 is a regulator of cardiac function
.
Proc. Nat. Acad. Sci. U.S.A.
,
106
,
20776
20781
.

14.

Bidwell
,
P.A.
,
Liu
,
G.S.
,
Nagarajan
,
N.
,
Lam
,
C.K.
,
Haghighi
,
K.
,
Gardner
,
G.
,
Cai
,
W.F.
,
Zhao
,
W.
,
Mugge
,
L.
,
Vafiadaki
,
E.
et al. (
2017
)
HAX-1 regulates SERCA2a oxidation and degradation
.
J. Mol. Cell. Cardiol.
,
114
,
220
233
.

15.

Vafiadaki
,
E.
,
Sanoudou
,
D.
,
Arvanitis
,
D.A.
,
Catino
,
D.H.
,
Kranias
,
E.G.
and
Kontrogianni-Konstantopoulos
,
A.
(
2007
)
Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function
.
J. Mol. Biol.
,
367
,
65
79
.

16.

Vafiadaki
,
E.
,
Papalouka
,
V.
,
Arvanitis
,
D.A.
,
Kranias
,
E.G.
and
Sanoudou
,
D.
(
2009
)
The role of SERCA2a/PLN complex, Ca(2+) homeostasis, and anti-apoptotic proteins in determining cell fate
.
Pflugers Arch.
,
457
,
687
700
.

17.

Lam
,
C.K.
,
Zhao
,
W.
,
Liu
,
G.S.
,
Cai
,
W.F.
,
Gardner
,
G.
,
Adly
,
G.
and
Kranias
,
E.G.
(
2015
)
HAX-1 regulates cyclophilin-D levels and mitochondria permeability transition pore in the heart
.
Proc. Natl. Acad. Sci. U S A
,
112
,
E6466
E6475
.

18.

Goldman
,
J.G.
,
Eichenseer
,
S.R.
,
Berry-Kravis
,
E.
,
Zimnowodzki
,
S.
,
Gregory
,
A.
,
Hogarth
,
P.
and
Hayflick
,
S.J.
(
2013
)
Clinical features of neurodegeneration with brain iron accumulation due to a C19orf12 gene mutation
.
Mov. Disord.
,
28
,
1462
1463
.

19.

Marmolino
,
D.
,
Manto
,
M.
,
Acquaviva
,
F.
,
Vergara
,
P.
,
Ravella
,
A.
,
Monticelli
,
A.
and
Pandolfo
,
M.
(
2010
)
PGC-1alpha down-regulation affects the antioxidant response in Friedreich’s ataxia
.
PLoS One
,
5
,
e10025
.

20.

Garcia-Gimenez
,
J.L.
,
Gimeno
,
A.
,
Gonzalez-Cabo
,
P.
,
Dasi
,
F.
,
Bolinches-Amoros
,
A.
,
Molla
,
B.
,
Palau
,
F.
and
Pallardo
,
F.V.
(
2011
)
Differential expression of PGC-1alpha and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts
.
PLoS One
,
6
,
e20666
.

21.

Shan
,
Y.
,
Schoenfeld
,
R.A.
,
Hayashi
,
G.
,
Napoli
,
E.
,
Akiyama
,
T.
,
Iodi Carstens
,
M.
,
Carstens
,
E.E.
,
Pook
,
M.A.
and
Cortopassi
,
G.A.
(
2013
)
Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich’s ataxia YG8R mouse model
.
Antioxid. Redox Signal.
,
19
,
1481
1493
.

22.

Reetz
,
K.
,
Dogan
,
I.
,
Costa
,
A.S.
,
Dafotakis
,
M.
,
Fedosov
,
K.
,
Giunti
,
P.
,
Parkinson
,
M.H.
,
Sweeney
,
M.G.
,
Mariotti
,
C.
,
Panzeri
,
M.
et al. (
2015
)
Biological and clinical characteristics of the European Friedreich's ataxia consortium for translational studies (EFACTS) cohort: a cross-sectional analysis of baseline data
.
Lancet Neurol.
,
14
,
174
182
.

23.

Weidemann
,
F.
,
Stork
,
S.
,
Liu
,
D.
,
Hu
,
K.
,
Herrmann
,
S.
,
Ertl
,
G.
and
Niemann
,
M.
(
2013
)
Cardiomyopathy of Friedreich ataxia
.
J. Neurochem.
,
126
(
Suppl 1
),
88
93
.

24.

Cossee
,
M.
,
Puccio
,
H.
,
Gansmuller
,
A.
,
Koutnikova
,
H.
,
Dierich
,
A.
,
LeMeur
,
M.
,
Fischbeck
,
K.
,
Dolle
,
P.
and
Koenig
,
M.
(
2000
)
Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation
.
Hum. Mol. Genet.
,
9
,
1219
1226
.

25.

Condo
,
I.
,
Ventura
,
N.
,
Malisan
,
F.
,
Tomassini
,
B.
and
Testi
,
R.
(
2006
)
A pool of extramitochondrial frataxin that promotes cell survival
.
J. Biol. Chem.
,
281
,
16750
16756
.

26.

Jiang
,
Y.
,
Zhang
,
W.
,
Kondo
,
K.
,
Klco
,
J.M.
,
St Martin
,
T.B.
,
Dufault
,
M.R.
,
Madden
,
S.L.
,
Kaelin
,
W.G.
, Jr.
and
Nacht
,
M.
(
2003
)
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways
.
Mol. Cancer Res.
,
1
,
453
462
.

27.

Guccini
,
I.
,
Serio
,
D.
,
Condo
,
I.
,
Rufini
,
A.
,
Tomassini
,
B.
,
Mangiola
,
A.
,
Maira
,
G.
,
Anile
,
C.
,
Fina
,
D.
,
Pallone
,
F.
et al. (
2011
)
Frataxin participates to the hypoxia-induced response in tumors
.
Cell Death Dis.
,
2
,
e123
.

28.

Paupe
,
V.
,
Dassa
,
E.P.
,
Goncalves
,
S.
,
Auchere
,
F.
,
Lonn
,
M.
,
Holmgren
,
A.
and
Rustin
,
P.
(
2009
)
Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia
.
PLoS One
,
4
,
e4253
.

29.

Deng
,
X.
,
Song
,
L.
,
Zhao
,
W.
,
Wei
,
Y.
and
Guo
,
X.B.
(
2017
)
HAX-1 protects glioblastoma cells from apoptosis through the Akt1 pathway
.
Front. Cell. Neurosci.
,
11
,
420
.

30.

Bidwell
,
P.A.
,
Liu
,
G.S.
,
Nagarajan
,
N.
,
Lam
,
C.K.
,
Haghighi
,
K.
,
Gardner
,
G.
,
Cai
,
W.F.
,
Zhao
,
W.
,
Mugge
,
L.
,
Vafiadaki
,
E.
et al. (
2018
)
HAX-1 regulates SERCA2a oxidation and degradation
.
J. Mol. Cell. Cardiol.
,
114
,
220
233
.

31.

Petrillo
,
S.
,
Piermarini
,
E.
,
Pastore
,
A.
,
Vasco
,
G.
,
Schirinzi
,
T.
,
Carrozzo
,
R.
,
Bertini
,
E.
and
Piemonte
,
F.
(
2017
)
Nrf2-inducers counteract neurodegeneration in Frataxin-silenced motor neurons: disclosing new therapeutic targets for Friedreich’s ataxia
.
Int. J. Mol. Sci.
,
18
,
2173
.

32.

Lynch
,
D.R.
,
Farmer
,
J.
,
Hauser
,
L.
,
Blair
,
I.A.
,
Wang
,
Q.Q.
,
Mesaros
,
C.
,
Snyder
,
N.
,
Boesch
,
S.
,
Chin
,
M.
,
Delatycki
,
M.B.
et al. (
2019
)
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
.
Ann. Clin. Transl. Neurol.
,
6
,
15
26
.

33.

Liu
,
J.
,
Tang
,
Q.
,
Li
,
S.
and
Yang
,
X.
(
2016
)
Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells
.
Oncotarget
,
7
,
86446
86456
.

34.

Sun
,
X.
,
Li
,
Y.
,
Zheng
,
M.
,
Zuo
,
W.
and
Zheng
,
W.
(
2016
)
MicroRNA-223 increases the sensitivity of triple-negative breast cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1
.
PLoS One
,
11
,
e0162754
.

35.

Wang
,
L.
,
Tian
,
D.
,
Hu
,
J.
,
Xing
,
H.
,
Sun
,
M.
,
Wang
,
J.
,
Jian
,
Q.
and
Yang
,
H.
(
2016
)
MiRNA-145 regulates the development of congenital heart disease through targeting FXN
.
Pediatr. Cardiol.
,
37
,
629
636
.

36.

Seco-Cervera
,
M.
,
Gonzalez-Rodriguez
,
D.
,
Ibanez-Cabellos
,
J.S.
,
Peiro-Chova
,
L.
,
Gonzalez-Cabo
,
P.
,
Garcia-Lopez
,
E.
,
Vilchez
,
J.J.
,
Sanz-Gallego
,
I.
,
Pallardo
,
F.V.
and
Garcia-Gimenez
,
J.L.
(
2017
)
Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients
.
Sci. Rep.
,
7
,
5237
.

37.

Dantham
,
S.
,
Srivastava
,
A.K.
,
Gulati
,
S.
and
Rajeswari
,
M.R.
(
2018
)
Differentially regulated cell-free microRNAs in the plasma of Friedreich’s ataxia patients and their association with disease pathology
.
Neuropediatrics
,
49
,
35
43
.

38.

Wang
,
H.
,
Chen
,
F.
,
Tong
,
J.
,
Li
,
Y.
,
Cai
,
J.
,
Wang
,
Y.
,
Li
,
P.
,
Hao
,
Y.
,
Tian
,
W.
,
Lv
,
Y.
et al. (
2017
)
Circulating microRNAs as novel biomarkers for dilated cardiomyopathy
.
J. Cardiol.
,
24
,
65
73
.

39.

Condo
,
I.
,
Ventura
,
N.
,
Malisan
,
F.
,
Rufini
,
A.
,
Tomassini
,
B.
and
Testi
,
R.
(
2007
)
In vivo maturation of human frataxin
.
Hum. Mol. Genet.
,
16
,
1534
1540
.

40.

Amati
,
F.
,
Diano
,
L.
,
Campagnolo
,
L.
,
Vecchione
,
L.
,
Cipollone
,
D.
,
Bueno
,
S.
,
Prosperini
,
G.
,
Desideri
,
A.
,
Siracusa
,
G.
,
Chillemi
,
G.
et al. (
2010
)
Hif1alpha down-regulation is associated with transposition of great arteries in mice treated with a retinoic acid antagonist
.
BMC Genomics
,
11
,
497
.

41.

Dabney
,
A.R.
and
Storey
,
J.D.
(
2007
)
Normalization of two-channel microarrays accounting for experimental design and intensity-dependent relationships
.
Genome Biol.
,
8
,
R44
.

42.

Gurtler
,
A.
,
Kunz
,
N.
,
Gomolka
,
M.
,
Hornhardt
,
S.
,
Friedl
,
A.A.
,
McDonald
,
K.
,
Kohn
,
J.E.
and
Posch
,
A.
(
2013
)
Stain-free technology as a normalization tool in western blot analysis
.
Anal. Biochem.
,
433
,
105
111
.

Author notes

The authors wish it to be known that, in their opinion, the first Francesca Tiano and Francesca Amati authors should be regarded as joint First Authors.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)